NCT02324621View on ClinicalTrials.gov

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

February 20, 2015

Primary Completion Date

October 18, 2018

Study Completion Date

October 23, 2018

Conditions

Unspecified Adult Solid Tumor

Interventions

DRUG

Oral ONC201

Given PO

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

Oncoceutics, Inc.

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

Oncoceutics, Inc.

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER